SVNS Solvonis Therapeutics Plc

RNS Reach - non-regulatory announcement

21 January 2025

Solvonis Therapeutics plc
("Solvonis Therapeutics" or the "Company")

Proactive Investors interview with CEO

Solvonis Therapeutics  (LON: SVNS), an innovative biotechnology company co-developing therapeutics for mental health disorders, announces an interview on Proactive Investors with Anthony Tennyson, CEO of the Company. The interview with Anthony Tennyson can be viewed now at https://www.proactiveinvestors.co.uk/companies/news/1064736/solvonis-therapeutics-says-fda-supports-phase-2b-for-awkn-002-candidate-1064736.html.

Enquiries:

Solvonis Therapeutics plc
Anthony Tennyson, CEO & Executive Director
Email: anthony@solvonis.com

Allenby Capital (Financial Adviser and Broker) +44 (0) 20 3328 5656

Nick Naylor / Liz Kirchner (Corporate Finance) | Guy McDougall (Sales)

About Solvonis Therapeutics plc

Solvonis Therapeutics plc is an innovative biotechnology company focused on developing intellectual property relating to the treatment of mental health and substance use disorders, and the co-development of therapeutics for mental health disorders.  Our mission is to improve outcomes for individuals suffering from these conditions, with an initial focus on trauma-related mental health disorders, such as PTSD, which affected approximately 13 million adults in the U.S. in 2020, with the Company estimating a current affected population of 20 million across the US, UK and key EU markets.

For more information, please visit www.graft polymer.co.uk and also www.solvonis.com

About Reach announcements

This is an RNS Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain.  Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.